Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
ST. LOUIS, April 27, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 first quarter ended March 31, 2017 on Monday, May 8, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2017 financial results conference call |
| When: | Monday, May 8th at 10:00 a.m. Eastern Time (7:00 a.m. PT) |
| Dial In Number: | To access the live call, dial 877-675-4756 (US and Canada) or 719-325-4839 (International) and give the participant pass code 3960816. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com |
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Monday, May 15, 2017. To access the replay dial-in information, please click here. |
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts: David L. Fischel Chairman and Acting Chief Executive Officer Martin C. Stammer Chief Financial Officer [email protected]
